TheranosticTrials.org

Clinical Trial · NCT05432947

68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients

Overview

PSMA is highly expressed on the cell surface of the microvasculature of several solid tumors, including clear cell renal cell carcinoma (ccRCC). This makes it a potentially imaging target for the detection of ccRCC. This pilot study was designed to evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 18F-FDG PET/CT in the same group of ccRCC patients.

Sponsor

Peking Union Medical College Hospital

Phase

N/A

Contacts

Zhaohui Zhu, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT05432947

Drug / Compound

P16-093

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: HBED-CC

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • patients with confirmed or suspected clear cell Renal cell carcinoma;
  • signed written consent.
  • 68Ga-P16-093 18F-FDG PET/CT within a week;

Exclusion

Exclusion criteria not yet provided.